Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$28.61
▲ $0.06 (+0.2%)
Market data updated: 09/20 04:12 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/20/2026
Market Cap
$4.57B
Day Range
$27.91 - $28.68
52-Week Range
$12.00 - $28.72
Beta
—
Next Earnings
03.11.2026
Support
$20.46
Resistance
$28.72
ADPT is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+107.8% (1Y)
Strengths: 17/33 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 54.8%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$7.43 vs. price $28.61 (-126.0%)
Fair Value
Signal tension
Growth scores strong (82/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
62
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
2d ago · $27.67
Evidence: Euphoria score crossed 55 (now 62)
What happened after
Still awaiting outcome
2d ago · $27.67
Evidence: FOMO score jumped from 12 to 59 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
82
Quality
58
Value
38
Momentum
81
Risk
48
Sentiment
92
Fundamental
30
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Adaptive Biotechnologies Corporation highlights its strong market performance, with its stock doubling over the past year. Analysts from firms like Piper Sandler, Morgan Stanley, and TD Cowen have maintained or upgraded their ratings, raising price targets to $22–$28, citing growth in its **clonoSEQ** MRD (minimal residual disease) diagnostics and improving margins. The company’s focus on pure-play MRD diagnostics and expanding adoption has been a key theme, alongside an insider selling shares in August. Adaptive is also set to participate in the **Morgan Stanley Global Healthcare Conference** in September.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Adaptive Biotechnologies Corporation. News trend score: 92. Reason: 9 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
72
🎯 Conviction (vs. Emotion)
45
Psychology
92
Fundamentals
30
Technical
81
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+63%
Market Narrative
81
Fundamental Reality
45
Narrative Gap
+36
🧠 StockIQ Psychologist
The market’s extreme sentiment (100/100) and overperformance (+33.3% above 200-day avg) drive euphoric behavior, despite weak momentum (-4.7% ROC). This suggests investors are prioritizing narrative-driven optimism over technical signals, creating a disconnect between price action and fundamentals. The narrative gap (14 points) further implies a divergence between market enthusiasm and underlying reality. The key question is whether this euphoria will sustain despite lagging momentum or if a reversion to mean is imminent. The paradox of low volatility (0.88x ATR) alongside negative momentum hints at latent panic selling signals, complicating the dominant euphoria.
Updated: 09/08/2026, 10:49 PM
What could change this?
👥 What the crowd believes
"Adaptive Biotechnologies… announced it will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference"
"raises the price target from $20 to $27.5"
🧠 Market Brain events driving this
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 90/100
🔴 Weakest match
Samuel Armstrong Nelson — 0/100
🗣️ Why do they disagree?
Based on Peter Lynch's documented principles, the model estimates a strong upside (score 90) because the price appears to lag growth, while Samuel Armstrong Nelson’s cycle lens (score 84) sees the stock as oversold and therefore favorably positioned. Philip Fisher (75) and Walter Bagehot (72) highlight exceptional quality and solid liquidity, yielding relatively high but more measured scores. Benjamin Graham’s value criteria (score 50) and his enterprising variant (score 44) produce mixed verdicts, indicating the stock is not sufficiently cheap for a value‑oriented entry. Market‑efficiency, crowd‑delusion, and cycle‑risk viewpoints (scores ranging from 45 to 32) add caution, suggesting limited edge over an index and late‑cycle risk. Finally, trend‑focused rules from Jesse Livermore (37) and disciplined‑setup standards from Jack Schwager (25) lead to negative assessments, reflecting a lack of a clear upward trend or a compelling trade setup.
Peter Lynch
One Up on Wall Street (1989)
🟢 90
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 77
Positive trend — the price action Livermore looked for
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 75
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 72
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 64
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 50
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 49
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 48
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 38
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 29
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 23
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 9
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 0
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (9 bullish · 2 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
74.2%
Operating Margin
-20.6%
Net Margin
-21.5%
EBITDA Margin
-14.8%
ROE
-27.2%
ROA
-11.6%
ROIC
—
EPS
-$0.39
Cash
$70.50M
Total Debt
$131.21M
Current Ratio
3.34
Debt/Equity
0.60
How is Fair Value calculated? →
Current Price
$28.61
Estimated Fair Value (DCF)
-$7.43
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-126.0%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
17.3%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 17.3% | $-57.39M | $-52.65M |
| 2 | 13.6% | $-65.17M | $-54.86M |
| 3 | 9.9% | $-71.61M | $-55.30M |
| 4 | 6.2% | $-76.04M | $-53.87M |
| 5 | 2.5% | $-77.94M | $-50.66M |
Base FCF (last actual year)
$-48.95M
Terminal Value
$-1.23B
Present Value of Terminal Value
$-798.84M
Enterprise Value
$-1.07B
Net Debt
$60.71M
Equity Value
$-1.13B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$1.44
Tangible Book Value per Share (Tangible NAV)
$0.65
Sentiment based on basic keywords (not AI) — 9 positive, 9 neutral, 2 negative out of the last 20 articles.
Yahoo · 17.9.2026
Benzinga · 17.9.2026
SeekingAlpha · 15.9.2026
Benzinga · 9.9.2026
Yahoo · 1.9.2026
GlobeNewswire · 1.9.2026
Yahoo · 24.8.2026
Trefis · 24.8.2026
Barchart · 21.8.2026
MT Newswires · 20.8.2026
Benzinga · 4.8.2026
SeekingAlpha · 31.7.2026
Benzinga · 30.7.2026
Benzinga · 30.7.2026
Benzinga · 30.7.2026
SeekingAlpha · 30.7.2026
MT Newswires · 30.7.2026
Benzinga · 30.7.2026
GuruFocus.com · 30.7.2026
SeekingAlpha · 30.7.2026
Adaptive Biotechnologies Corporation (ADPT) currently has a StockIQ AI score of 62/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ADPT currently scores 62/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ADPT's estimated fair value is -$7.43, which is 126.0% below the current price of $28.61. This is one valuation model among several signals in the fair-value category, not a price target.
ADPT's technical score is 81/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 54.8%; Earnings per share (EPS) growth: 63.9%; Free cash flow growth: 50.5%.
Based on the real signals StockIQ computed: Estimated fair value: -$7.43 vs. price $28.61 (-126.0%); Operating margin: -20.6% (negative); Net margin: -21.5% (negative).
StockIQ has no recorded dividend payment history for ADPT.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 16 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| OWEN KATEY EINTERZ | Gift | 31.8.2026 | 12,539 | -12,539 | — |
| OWEN KATEY EINTERZ | Open Market Sale | 26.8.2026 | 78,639 | -9,615 | $26.00 |
| OWEN KATEY EINTERZ | Open Market Sale | 26.8.2026 | 9,615 | -9,615 | $26.00 |
| HERSHBERG ROBERT | Exercise of Derivative Securities | 18.8.2026 | 15,000 | +15,000 | $6.32 |
| ROBINS CHAD M | Open Market Sale | 18.8.2026 | 204 | -204 | $25.14 |
| ROBINS CHAD M | Open Market Sale | 18.8.2026 | 278,472 | -278,472 | $24.48 |
| HERSHBERG ROBERT | Open Market Sale | 18.8.2026 | 15,664 | -15,664 | $24.41 |
| ROBINS CHAD M | Exercise of Derivative Securities | 18.8.2026 | 278,676 | -278,676 | — |
| HERSHBERG ROBERT | Exercise of Derivative Securities | 18.8.2026 | 15,000 | -15,000 | — |
| ROBINS CHAD M | Exercise of Derivative Securities | 18.8.2026 | 278,676 | +278,676 | $6.55 |
| HERSHBERG ROBERT | Open Market Sale | 18.8.2026 | 15,000 | -15,000 | $24.39 |
| NEUPERT PETER M | Open Market Sale | 17.8.2026 | 40,000 | -40,000 | $25.10 |
| ROBINS CHAD M | Exercise of Derivative Securities | 17.8.2026 | 321,324 | -321,324 | — |
| NEUPERT PETER M | Exercise of Derivative Securities | 17.8.2026 | 15,000 | +15,000 | $6.32 |
| NEUPERT PETER M | Exercise of Derivative Securities | 17.8.2026 | 15,000 | -15,000 | — |
| NEUPERT PETER M | Open Market Sale | 17.8.2026 | 69,690 | -69,690 | $25.16 |
| NEUPERT PETER M | Open Market Sale | 17.8.2026 | 15,000 | -15,000 | $25.23 |
| ROBINS CHAD M | Exercise of Derivative Securities | 17.8.2026 | 321,324 | +321,324 | $6.55 |
| ROBINS CHAD M | Open Market Sale | 17.8.2026 | 318,799 | -318,799 | $25.08 |
| ROBINS CHAD M | Open Market Sale | 17.8.2026 | 2,525 | -2,525 | $25.57 |
| BOBULSKY SUSAN | Open Market Sale | 10.8.2026 | 396,989 | -3,000 | $25.00 |
| BOBULSKY SUSAN | Open Market Sale | 10.8.2026 | 3,000 | -3,000 | $25.00 |
| BOBULSKY SUSAN | Open Market Sale | 30.7.2026 | 1,299 | -1,299 | $24.00 |
| BOBULSKY SUSAN | Open Market Sale | 30.7.2026 | 399,989 | -1,299 | $24.00 |
| ROBINS HARLAN S | Open Market Sale | 21.7.2026 | 213,702 | -213,702 | $22.12 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
11,712,796 shares short as of 2026-08-31 · vs. 12,490,395 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
49.5% of trading volume this week was short selling, vs. 37.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology